Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Generalized anxiety disorder (GAD), a prevalent and chronic illness, is associated with dysregulation in both serotonergic and noradrenergic neurotransmission. Our study examined the efficacy, safety, and tolerability of duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, for short-term treatment of adults with GAD. In a 10-week, double-blind, progressive-titration, flexible-dose trial, 327 adult outpatients with a DSM-IV-defined GAD diagnosis were randomized to duloxetine 60-120 mg (DLX, N=168) or placebo (PLA, N=159) treatment. The primary efficacy measure was mean change from baseline to endpoint in Hamilton Anxiety Scale (HAMA) total score. Secondary outcome measures included response rate (HAMA total score reduction > or =50% from baseline), Clinician Global Impression-Improvement (CGI-I) scores, and Sheehan Disability Scale (SDS) scores. Patients who received duloxetine treatment demonstrated significantly greater improvement in HAMA total scores (P=.02); a higher response rate (P=.03), and greater improvement (P=.04) than patients who received placebo. Duloxetine-treated patients were also significantly more improved than placebo-treated patients on SDS global functional (P<.01) and work, social, and family/home impairment scores (P<.05). The rate of discontinuation due to adverse events (AEs) was higher for the duloxetine group compared with the placebo group (P=.002). The AEs most frequently associated with duloxetine were nausea, dizziness, and somnolence. Duloxetine was an efficacious, safe, and well-tolerated treatment that resulted in clinically significant improvements in symptom severity and functioning for patients with GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Shear, M. K., Vander Bilt, J., Rucci, P., Endicott, J., Lydiard, B., Otto, M. W., Pollack, M. H., Chandler, L., Williams, J., Ali, A., et al. (2001) · Depression and Anxiety · doi:10.1002/da.1033 · Cited by 483
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Self-citationBELZER, K., & SCHNEIER, F. R. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200409000-00003 · Cited by 235
The rater applied performance scale: development and reliability
Lipsitz, J., Kobak, K., Feiger, A., Sikich, D., Moroz, G., & Engelhard, A. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.03.001 · Cited by 31
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Effects of short-term exercise training on signs and symptoms of generalized anxiety disorder
Herring, M. P., Jacob, M. L., Suveg, C., & O’Connor, P. J. (2011) · Mental Health and Physical Activity · doi:10.1016/j.mhpa.2011.07.002 · Cited by 93
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Kaplan, A., Franzen, M. D., Nickell, P. V., Ransom, D., & Lebovitz, P. J. (2014) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.838632 · Cited by 54
Choy, E. H. S., Mease, P. J., Kajdasz, D. K., Wohlreich, M. M., Crits-Christoph, P., Walker, D. J., & Chappell, A. S. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1203-2 · Cited by 47
“disorder (GAD), diabetic peripheral neuropathic pain (DPNP), and FM [18–32].”
BackgroundIncidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Comprehensive review of generalized anxiety disorder in primary care in Europe.
Parmentier, H., García-Campayo, J., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.770731 · Cited by 37
Pollack, M. H., Endicott, J., Liebowitz, M., Russell, J., Detke, M., Spann, M., Ball, S., & Swindle, R. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.11.006 · Cited by 35
Self-citationAntidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Metadata
- Authors
- Rynn, M., Russell, J., Erickson, J., Detke, M. J., Ball, S., Dinkel, J., Rickels, K., & Raskin, J.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2008
- Volume
- 25
- Issue
- 3
- Pages
- 182-189
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2040179400
- Cited by
- 144
- References
- 6
- FWCI
- 22.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.